Compulsory Licensing: How Governments Override Patents to Protect Public Health

When a life-saving drug is priced out of reach for millions, who gets to decide if it’s sold cheaper? That’s where compulsory licensing comes in. It’s not a loophole. It’s not a secret backdoor. It’s a legal tool written into international trade law that lets governments step in and authorize generic versions of patented medicines - even if the drug company says no.

Think about it: a pharmaceutical company spends years and billions developing a new cancer drug. They get a patent. That patent gives them a monopoly. For 20 years, they’re the only one allowed to make and sell it. That’s how they recoup their investment. But what if that drug costs $100,000 a year, and a country has 50,000 people who need it? No one can afford it. That’s not a market failure. That’s a public health crisis. And compulsory licensing is the legal way out.

How Compulsory Licensing Works

At its core, compulsory licensing is simple: the government says, "We need this drug now, and we’re going to let someone else make it." The patent holder doesn’t lose ownership. They don’t lose their patent. But they lose control over who can produce it. In return, they get paid - "adequate remuneration," as the World Trade Organization calls it. That means fair compensation, not nothing.

This isn’t new. The idea dates back to the 1883 Paris Convention. But it got real teeth in 1994 with the TRIPS Agreement. That’s the global rulebook for patents, and it says countries can issue compulsory licenses under certain conditions. The big ones? You can’t just do it for fun. You have to prove there’s a public need - like a disease outbreak, a shortage, or prices that are absurdly high. You usually have to try to negotiate with the patent holder first. But if there’s an emergency? That rule gets waived. Time doesn’t matter. Lives do.

Where It’s Used - And Where It’s Not

The U.S. has the legal tools, but rarely uses them. There are three ways it can happen. One is under Title 28, U.S.C. §1498 - which lets the federal government use a patent without permission if it’s for national defense or public health. The government pays, but the patent holder can’t stop them. Between 1945 and 2020, the U.S. issued only 10 of these. All for military or government use. Never for a medicine.

Then there’s the Bayh-Dole Act. If a drug was developed with federal research money - say, from NIH - the government can force a license if the company isn’t making it available. Sounds powerful, right? But since 1980, the NIH has received 12 petitions. Not one was granted. Why? They always say the company is "taking effective steps." Even if the drug costs $500 a pill and only 1,000 people get it.

Meanwhile, countries like India, Brazil, and Thailand have used compulsory licensing as a lifeline. India issued 22 compulsory licenses for cancer drugs between 2005 and 2021. The most famous? Nexavar, a kidney and liver cancer drug made by Bayer. It cost $5,500 a month. India licensed it to a local company. The generic version? $175 a month. That’s a 96% drop. Patients who couldn’t afford treatment could suddenly get it. And Bayer? They got paid. Not as much as before. But they got paid.

Thailand did something similar with HIV drugs. Lopinavir/ritonavir went from $1,200 a year to $230. Efavirenz dropped from $550 to $200. These weren’t charity cases. These were legal decisions backed by public health data. And the results? Millions more people got treatment.

The Global Debate

Drug companies say compulsory licensing kills innovation. They point to a 2018 study that found countries with active licensing programs saw 15-20% less pharmaceutical R&D investment. They argue that if companies can’t make money, they won’t risk billions on new drugs.

But the counterargument is just as strong. Dr. Ellen ‘t Hoen, a leading expert on medicines policy, says the negotiation requirement in TRIPS is a delay tactic. During a pandemic, waiting weeks for a company to respond isn’t "reasonable." It’s deadly. And Professor Jorge Contreras found that in 83% of cases where compulsory licenses were issued, drug prices dropped by 65-90%. That’s not a threat to innovation. That’s access.

Even the industry admits it. The IFPMA says each compulsory license announcement causes an 8.2% drop in stock prices. Why? Because the market knows: if a country issues a license, the drug’s monopoly ends. The price crashes. Revenue plummets. That’s the real fear - not that innovation stops, but that profits do.

And here’s the twist: the threat of compulsory licensing often works better than the license itself. Since 2000, 90% of HIV drugs in low-income countries got price cuts just because governments threatened to issue licenses. Companies lowered prices to avoid it. That’s power. Not destruction.

What Changed After COVID-19

The pandemic forced the world to rethink patents. In March 2020, 40 countries - including Germany, Canada, and Israel - prepared to issue compulsory licenses for coronavirus tests, treatments, and vaccines. The U.S. didn’t. But the WTO did.

In June 2022, member states agreed to a temporary waiver. For the first time, countries could produce COVID-19 vaccines without patent holder consent. It was historic. But implementation? Slow. By October 2023, only 12 facilities in 8 countries were authorized. Why? Bureaucracy. Technical barriers. Lack of manufacturing capacity. The law was there. The will wasn’t.

Now, the EU is pushing further. In 2023, they proposed a rule that would force patent holders to offer licensing terms within 30 days - or face automatic compulsory licensing. That’s a game-changer. No more waiting. No more stalling. If you won’t license, we’ll take it.

The Real Challenge: Implementation

Having the law isn’t enough. You need the capacity to use it. The WHO found that 60% of low- and middle-income countries don’t have the legal, technical, or administrative tools to issue a license. They can’t draft the notice. They can’t evaluate the drug’s value. They can’t calculate fair compensation.

India and Brazil have systems. They have courts, patent offices, health agencies working together. The U.S. has the law, but no clear process for public health emergencies. The process for a Bayh-Dole petition? It takes years. And even then, it rarely works.

Compensation is another headache. In the U.S., courts use the "Georgia-Pacific factors" - 15 different criteria to figure out how much to pay. In India, they use a simple formula: 6% of net sales. Simple. Transparent. Predictable.

And then there’s the export clause. The WTO created a special rule in 2005 to let countries without drug factories import generics made under compulsory license. Canada used it once - to send HIV drugs to Rwanda in 2012. That’s it. No other country has used it. The system is too complex. Too slow. Too expensive.

What’s Next?

The future of compulsory licensing is being written right now. The WHO is negotiating a Pandemic Treaty. One draft article says: when a global health emergency is declared, essential medicines must be automatically licensed. No negotiation. No delay. Just production.

That’s the direction. Not to abolish patents. But to make them flexible. To treat health like a human right - not a profit margin.

Compulsory licensing isn’t about stealing patents. It’s about balancing power. It’s about saying: when lives are on the line, the patent system can’t be the only rulebook. Governments have a duty to act. And the law lets them.